[Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial]

Urologe A. 2020 Jun;59(6):723-724. doi: 10.1007/s00120-020-01176-y.
[Article in German]
No abstract available

MeSH terms

  • Androgen Antagonists / therapeutic use
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Disease-Free Survival
  • Docetaxel / therapeutic use
  • Humans
  • Male
  • Neoplasm Metastasis
  • Prostatic Neoplasms* / drug therapy

Substances

  • Androgen Antagonists
  • Docetaxel